Abstract: FR-PO0681
Real-World Clinical Outcomes, Patient Outcomes, and Physician Experience with the Eculizumab Biosimilar BEKEMV in Patients with Atypical Haemolytic Uremic Syndrome
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - ANCA/FSGS
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Servin, Argentina E., Amgen Inc, Thousand Oaks, California, United States
- Moore, Carol, Amgen Inc, Thousand Oaks, California, United States
- Morton, Ella, Adelphi Real World, Bollington, England, United Kingdom
- Harvey, Mia C V J, Adelphi Real World, Bollington, England, United Kingdom
- Wojcik, Cezary, Amgen Inc, Thousand Oaks, California, United States
Background
Atypical haemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy triggering thrombocytopenia, haemolytic anaemia and ischaemic organ damage. This study describes real-world clinical and patient outcomes, as well as satisfaction with BEKEMV.
Methods
Data were drawn from the Adelphi Real World Disease Specific Programme™, a cross-sectional survey with retrospective data collection of physicians and adult patients with aHUS receiving BEKEMV in Germany and Italy (October-December 2025). Physicians reported patient demographics and outcomes. Patients completed the Kidney Disease Quality of Life (KD-QoL, 0-100; higher scores indicate better QoL). Analyses were descriptive.
Results
Twenty-three physicians reported data for 44 patients (18 previously switched from other C5 monoclonal antibodies; 26 treatment-naïve). Patient characteristics are shown in Table 1. Mean±SD age was 40±15 years; 64% were female. In the year prior to survey, 29% of patients were hospitalised.
At survey, 89% of patients (n=39) were in remission; of those not in remission (n=5), 80% were improving. QoL was good-to-excellent in 71% of patients, and 68% had physician-perceived mild disease (Figure 1).
Physician-perceived adherence of ≥80% was reported for 91% of patients. Physician satisfaction or complete satisfaction was reported for 89% of patients, with 11% being neither satisfied nor dissatisfied. Among patients with KD-QoL data (n=21), mean±SD scores were 70±17 for kidney disease effects and 72±18 for symptoms/problems.
Conclusion
Despite the small sample size, patients receiving BEKEMV had high remission rates and favourable QoL outcomes, indicating effective disease control despite persistent renal impairment in some patients. These real-world findings support BEKEMV as an effective treatment option for aHUS.